RNS Number : 4281H BSF Enterprise PLC 08 June 2026 08 June 2026 BSF Enterprise PLC Result of General Meeting BSF Enterprise PLC (LSE: BSFA) ("BSF" or the "Company"), a leading innovator in tissue-engineered materials, is pleased to announce that at the Company's General Meeting held earlier today, all resolutions proposed were duly passed by shareholders by way of a poll, the results of which were as follows: Resolution Shares For % of votes Against % of votes * Withheld Ordinary Resolution: 1. Directors' authority to allot shares for specific purposes 38,811,710 97.35% 1,057,257 2.65% 94 Ordinary Resolution: 2. Directors' authority to allot shares for general purposes 38,358,885 97.30% 1,063,893 2.70% 446,283 Special Resolution: 3. Disapplication of pre- emption rights for specific purposes 38,809,545 97.34% 1,059,422 2.66% 94 Special Resolution: 4. Disapplication of pre- emption rights for general purposes 38,345,356 97.27% 1,077,422 2.73% 446,283 A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" any of the Resolutions. Following the passing of the Resolutions, an application has been made for 26,875,000 ordinary shares to be admitted to listing on the Equity Shares (transition) category of the Official List and to trading on the London Stock Exchange's main market for listed securities ("Admission") being 25,000,000 new ordinary shares pursuant to the Placing announced by the Company on 03 June in 2026 ("Placing Shares") and 1,875,000 new ordinary shares ("Fee Shares") in settlement of certain advisory fees. It is expected that Admission of the Placing Shares and Fee Shares will become effective on or around 8.00 a.m. on 12 June 2026. Total Voting Rights Following Admission, the Company's enlarged share capital will comprise 193,749,437 ordinary shares of 1 penny each. Therefore, the total number of voting rights in the Company will be 193,749,437. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in the Company, or a change to their interest in the Company, under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. This announcement contains inside information for the purposes of Article 7 of Regulation 2014/596/EU which is part of domestic UK law pursuant to the Market Abuse (Amendment) (EU Exit) regulations (SI 2019/310). END Engage with the BSF Enterprise management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor website here: https://bsfenterprise.com/link/ejnLne For further enquiries, please visit www.bsfenterprise.com or contact: BSF Enterprise PLC Geoff Baker - Chairman Che Connon - CEO & Director We encourage all investors to share questions on this announcement via our investor website. https://bsfenterprise.com/s/a1f22b Bowsprit Partners John Treacy James Sheehan +44 (0)203 883 4430 ISIN of the Ordinary Shares is GB00BHNBDQ51. SEDOL Code is BHNBDQ5. Subscribe to our news alert service: https://bsfenterprise.com/s/bb9f43 About BSF Enterprise PLC BSF Enterprise PLC (LSE:BSFA) develops and commercialises cutting-edge tissue-engineered solutions, including lab-grown leather (via LGL), cultivated meat, and corneal repair technologies. By leveraging its proprietary scaffold-free ATEP™ platform, BSF delivers sustainable, high-performance alternatives to conventional materials, targeting global markets where provenance, ethics, and performance are increasingly prized by consumers and brands alike. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ROMBVLFBQQLEBBV